IKS073
Iksuda's first ProAlk-ADC program: a best-in-class ADC in IND-enabling studies for solid tumors.
IKS073 has been designed to provide a best-in-class therapy with raised TI and wider utility over in-clinic and on-market competitors - resulting from tumor-selective enzymatic release of Iksuda's protein alkylating payload, ProAlkTM.
Iksuda's ProAlk free payload (ProAlk01) shows high activity across a broad range of tumors, with consistently high potency for those cancers associated with an over-expression of B7H3.
Like all our ADCs, the payload is delivered via glucuronide-driven tumor-selective activation for added precision and safety.
In preclinical studies, IKS073 is associated with high anti-cancer activity across a range of relevant xenograft models, with MEDs < 0.3 mg/kg, including in NSCLC and TNBC.
In toxicology studies in non-human primates, it is well tolerated in single or repeat dose regimens at doses of ten- to ≥ twenty-fold the MEDs in mouse xenografts, enabling a high, clinically relevant TI for onward testing in-clinic.
IKS073 contains Iksuda's PermaLink conjugation chemistry which ensures high ADC stability.
Iksuda deepens clinical pipeline
Iksuda Therapeutics deepens clinical pipeline through licensing agreement for Her2 antibody drug conjugate programme from LegoChem Biosciences
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates
Expanded agreement grants Iksuda access to Legochem Biosciences’ next generation ADC platform for up to six targets
Forging stable relationships for Antibody-Drug Conjugates
DCs are a class of biopharmaceuticals that target cancer cells while leaving healthy cells alone.
Keep informed
Sign up for our latest programme news and insights
